...
首页> 外文期刊>BJU international >Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?
【24h】

Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

机译:每日5型磷酸二酯酶抑制剂治疗:前列腺炎/前列腺痛的新治疗选择?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The management of patients with chronic pelvic pain attributed to chronic prostatitis has always been rather unsatisfactory. Even prolonged treatment with an aminoquinolone, such as ciprofloxacin, and an anti-inflammatory agent, or, alternatively an oc-blocker, seldom results in rapid resolution of the symptoms, and is commonly completely ineffective.There is in fact a very reasonable rationale for the use of a long-acting phosphodiesterase type 5 (PDE5) inhibitor in the treatment of men with symptoms of abacterial prostatitis/prostatodynia. The underlying cause of these symptoms has long been a source of speculation. In the absence of an identifiable infective agent, the current widespread use of antibiotics as a treatment option defies logic. Over 30 years ago, Kirby et al. [1] suggested that intraprostatic reflux of urine might be an important initiating factor. In 2007, Grimsley et al. [2] suggested that PDE5 inhibitors might relax the smooth muscle in the prostatic ducts and thereby have a role in the management of prostatitis, but provided no evidence for the hypothesis.
机译:归因于慢性前列腺炎的慢性盆腔痛患者的治疗一直不尽人意。即使长时间使用氨基喹诺酮(例如环丙沙星)和抗炎药或oc阻滞剂进行治疗,也很少能迅速缓解症状,并且通常是完全无效的。事实上,对于使用长效5型磷酸二酯酶(PDE5)抑制剂治疗患有细菌性前列腺炎/前列腺痛症状的男性。这些症状的根本原因长期以来一直是猜测的来源。在没有可识别的传染原的情况下,当前抗生素作为治疗选择的广泛使用违反了逻辑。 30多年前,Kirby等人。 [1]提示前列腺内尿液反流可能是重要的启动因素。 2007年,Grimsley等人。 [2]提示PDE5抑制剂可能会使前列腺导管中的平滑肌松弛,从而在前列腺炎的治疗中发挥作用,但没有提供有关这一假说的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号